Reimbursed Care Access in Bahrain

Currently classified as a strictly controlled substance under Bahrain’s narcotics and psychotropic substances framework, with no authorized medical use outside of approved clinical research. This legal posture is enforced under Bahrain’s narcotics law and NHRA regulatory framework which reserves tightly controlled status for illicit psychoactive substances and permits only tightly regulated medical/scientific research subject to ministerial/NHRA approval. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Possession, importation, manufacture, or trafficking of MDMA attract severe criminal penalties under Bahraini narcotics law; any clinical use would require explicit NHRA and ministerial authorization. # #

There is no publicly available NHRA record or formal NHRA/Ministry of Health publication indicating marketing authorization or reimbursement for intranasal esketamine (Spravato) in Bahrain as of Feb 20, 2026; NHRA handles medicine registration and the regulation of narcotic/psychotropic substances and maintains the authoritative register for permitted medicinal products. Esketamine is therefore not recognized in publicly available Bahraini regulatory listings as an approved, reimbursed treatment; importation, use, or provision would require NHRA approval and prescribing within authorized health facilities. # #

Note: ketamine (the racemate) is a long‑established anesthetic and may be supplied to hospitals under medical controls, but branded esketamine preparations require explicit product registration and local reimbursement decisions which are not present in the NHRA public listings reviewed.

Ketamine is a controlled medicine that is legally used in Bahrain within licensed medical facilities for anesthesia and other accepted clinical indications under NHRA regulation; its distribution and clinical use are subject to the registration, prescribing and hospital supply controls administered by NHRA and the laws governing narcotic/psychotropic substances. The NHRA is the regulatory authority for medicines and for setting conditions on controlled substances and the Medicines/Health Insurance laws apply to clinical provision of hospital therapies. Publicly available Bahraini law and NHRA materials indicate controlled but permitted medical use rather than an outright prohibition. # # #

Reimbursement/coverage note: Bahrain’s Health Insurance Law (Law No. 23 of 2018) and hospital financing arrangements govern coverage for inpatient procedures and therapies provided in the public system, but there is no NHRA-published, compound‑specific national reimbursement schedule for ketamine psychiatric use; supply and payment depend on clinical setting (public hospital vs private clinic) and the usual hospital/pharmacy procurement and insurance arrangements.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Importation, possession, or use outside authorized scientific protocols is prohibited and subject to severe penalties. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. The substance is treated like other potent tryptamine psychedelics under Bahraini narcotics legislation. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no regulatory pathway in Bahrain for routine clinical ibogaine therapy outside tightly controlled research authorization. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Use or importation of ayahuasca (containing DMT) would fall under prohibitions on psychotropic substances unless otherwise authorised by NHRA for research. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Mescaline and peyote‑type materials are prohibited under Bahraini narcotics controls absent specific NHRA/ministerial research authorization. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Synthetic phenethylamine psychedelics such as 2C‑series compounds are covered by Bahraini psychotropic controls and criminal law. # #